EUVIMEDEUVIMED entdecken
Crossref

Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway

Shuai Teng, Zhaowei Zhu, Chenkai Wu, Yuhu He, Shenghua Zhou

International Immunopharmacology · 2023

DOI: 10.1016/j.intimp.2023.110198 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Shuai Teng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: NF-kappa B, HMGB1 Protein. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The contractile-syntheticphenotypicconversion of vascular smooth muscle cells (VSMCs) plays a key role in atherosclerosis, vascular restenosis, and hypertension. Our previous study explored the correlation between high mobility group box protein (HMGB) 1 and HMGB2 and neointimal hyperplasia after vascular injury. In the present study, we explore whether inflachromene (ICM), a novel inhibitor of the expression of both HMGB1 and HMGB2, modulates phenotypic changes in VSMCs and the mechanisms involved. Mice treated with ICM after carotid artery wire injury showed a decrease in excessive neointimal hyperplasia compared with that in the vehicle groups. In cultured VSMCs, pretreatment with ICM suppressed the angiotensin II (Ang II)-induced phenotypic conversion, proliferation, and migration. We discovered that ICM reduced the Ang II-induced upregulation of the expression of HMGB1 and HMGB2 and inhibited their shuttling between the nucleus and the cytosol. Mechanistically, Ang II-treated VSMCs exhibited higher levels of Toll-like receptor 4 (TLR4) and nuclear factor-κB (NF-κB) phosphorylation, which were attenuated by ICM. In addition, the NF-κB inhibitor Bay-117082 abolished the recombinant HMGB1-mediated VSMC phenotypic conversion, proliferation, and migration. Furthermore, ICM ameliorated the Ang II-induced increases in NAD[P]H oxidase expression, thereby attenuating the Ang II-induced proliferation and migration. These results reveal that ICM pretreatment attenuates Ang II-induced VSMC dedifferentiation, proliferation, and migration may by regulating the TLR4-NF-kB pathway. Thus, ICM is a potential therapy and preventive treatment for vascular proliferative diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NF-kappa BHMGB1 ProteinMiceAnimalsHyperplasiaToll-Like Receptor 4Cell ProliferationHMGB2 ProteinAngiotensin IICells, CulturedMyocytes, Smooth MuscleHeterocyclic Compounds, 4 or More Rings

Stichwörter der Autor:innen

Angiotensin IIHMGB1HMGB2InflachromeneNF-κBVascular smooth muscle cell

Substanzen

NF-kappa BToll-Like Receptor 4HMGB1 ProteinHMGB2 ProteinAngiotensin IIinflachromeneHeterocyclic Compounds, 4 or More RingsTlr4 protein, mouse

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
  • Department of Cardiovascular Medicine, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China. Electronic address: zhoushenghua@csu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Teng, S., Zhu, Z., Wu, C., He, Y., & Zhou, S. (2023). Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110198

Vancouver

Teng S, Zhu Z, Wu C, He Y, Zhou S. Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110198

BibTeX
@article{Teng2023,
  author = {Teng, Shuai and Zhu, Zhaowei and Wu, Chenkai and He, Yuhu and Zhou, Shenghua},
  title = {Inflachromene inhibits intimal hyperplasia through the HMGB1/2- regulated TLR4-NF-κB pathway},
  journal = {International Immunopharmacology},
  year = {2023},
  doi = {10.1016/j.intimp.2023.110198}
}
Kostenlos starten →